DekaBank Deutsche Girozentrale’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.2M | Hold |
115,973
| – | – | 0.03% | 369 |
|
|
2026
Q1 | $15.5M | Hold |
115,973
| – | – | 0.03% | 370 |
|
|
2025
Q4 | $17.7M | Hold |
115,973
| – | – | 0.03% | 356 |
|
|
2025
Q3 | $16.2M | Hold |
115,973
| – | – | 0.03% | 359 |
|
|
2025
Q2 | $14.5M | Sell |
115,973
-250
| -0.2% | -$28.7K | 0.03% | 375 |
|
|
2025
Q1 | $12.9M | Buy |
116,223
+250
| +0.2% | +$31.7K | 0.03% | 381 |
|
|
2024
Q4 | $16M | Hold |
115,973
| – | – | 0.03% | 356 |
|
|
2024
Q3 | $13.2M | Buy |
115,973
+2,387
| +2% | +$327K | 0.02% | 404 |
|
|
2024
Q2 | $15.2M | Sell |
113,586
-2,637
| -2% | -$362K | 0.03% | 372 |
|
|
2024
Q1 | $15.9M | Buy |
116,223
+46,627
| +67% | +$6.37M | 0.03% | 359 |
|
|
2023
Q4 | $9.14M | Buy |
69,596
+15,367
| +28% | +$1.77M | 0.02% | 455 |
|
|
2023
Q3 | $6.21M | Buy |
54,229
+1,955
| +4% | +$206K | 0.01% | 502 |
|
|
2023
Q2 | $4.92M | Buy |
52,274
+2,831
| +6% | +$277K | 0.01% | 557 |
|
|
2023
Q1 | $4.88M | Sell |
49,443
-132
| -0.3% | -$13.7K | 0.01% | 550 |
|
|
2022
Q4 | $5.92M | Buy |
49,575
+501
| +1% | +$58.7K | 0.02% | 502 |
|
|
2022
Q3 | $4.99M | Buy |
49,074
+5,134
| +12% | +$521K | 0.01% | 526 |
|
|
2022
Q2 | $4.28M | Sell |
43,940
-87
| -0.2% | -$8.03K | 0.01% | 562 |
|
|
2022
Q1 | $4.2M | Buy |
44,027
+1,272
| +3% | +$108K | 0.01% | 597 |
|
|
2021
Q4 | $3.58M | Buy |
42,755
+7,670
| +22% | +$706K | 0.01% | 642 |
|
|
2021
Q3 | $3.31M | Sell |
35,085
-718
| -2% | -$67.8K | 0.01% | 628 |
|
|
2021
Q2 | $3.45M | Buy |
35,803
+684
| +2% | +$65.6K | 0.01% | 609 |
|
|
2021
Q1 | $3.33M | Buy |
35,119
+5,768
| +20% | +$605K | 0.01% | 583 |
|
|
2020
Q4 | $2.74M | Sell |
29,351
-1,457
| -5% | -$141K | 0.01% | 596 |
|
|
2020
Q3 | $2.97M | Buy |
30,808
+24,370
| +379% | +$2.82M | 0.01% | 510 |
|
|
2020
Q2 | $803K | Buy |
6,438
+2,050
| +47% | +$227K | 0.01% | 704 |
|
|
2020
Q1 | $399K | Sell |
4,388
-2,330
| -35% | -$228K | ﹤0.01% | 801 |
|
|
2019
Q4 | $739K | Sell |
6,718
-21,613
| -76% | -$2.26M | ﹤0.01% | 760 |
|
|
2019
Q3 | $2.56M | Sell |
28,331
-78,880
| -74% | -$7.37M | 0.02% | 478 |
|
|
2019
Q2 | $8.83M | Buy |
107,211
+35,131
| +49% | +$2.88M | 0.04% | 331 |
|
|
2019
Q1 | $8.8M | Buy |
72,080
+9,550
| +15% | +$798K | 0.05% | 332 |
|
|
2018
Q4 | $4.42M | Sell |
62,530
-9,550
| -13% | -$915K | 0.03% | 377 |
|
|
2018
Q3 | $8.8M | Sell |
72,080
-1,520
| -2% | -$172K | 0.05% | 335 |
|
|
2018
Q2 | $7.16M | Buy |
73,600
+30,000
| +69% | +$2.69M | 0.05% | 349 |
|
|
2018
Q1 | $3.61M | Sell |
43,600
-68,900
| -61% | -$5.82M | 0.02% | 447 |
|
|
2017
Q4 | $6.02M | Hold |
112,500
| – | – | 0.05% | 337 |
|
|
2017
Q3 | $6.02M | Sell |
112,500
-8,000
| -7% | -$422K | 0.05% | 339 |
|
|
2017
Q2 | $5.57M | Sell |
120,500
-14,000
| -10% | -$679K | 0.04% | 359 |
|
|
2017
Q1 | $5.62M | Buy |
134,500
+50,700
| +61% | +$2.17M | 0.05% | 318 |
|
|
2016
Q4 | $3.18M | Sell |
83,800
-71,500
| -46% | -$3.24M | 0.03% | 395 |
|
|
2016
Q3 | $7.82M | Sell |
155,300
-96,800
| -38% | -$4.82M | 0.09% | 232 |
|
|
2016
Q2 | $11.4M | Sell |
252,100
-3,700
| -1% | -$170K | 0.13% | 182 |
|
|
2016
Q1 | $9.5M | Buy |
255,800
+136,100
| +114% | +$5.4M | 0.11% | 199 |
|
|
2015
Q4 | $6.76M | Buy |
119,700
+76,700
| +178% | +$3.9M | 0.08% | 246 |
|
|
2015
Q3 | $1.71M | Buy |
43,000
+1,500
| +4% | +$72.5K | 0.02% | 472 |
|
|
2015
Q2 | $1.98M | Buy |
41,500
+1,600
| +4% | +$67.8K | 0.02% | 448 |
|
|
2015
Q1 | $1.58M | Sell |
39,900
-800
| -2% | -$28.6K | 0.02% | 488 |
|
|
2014
Q4 | $906K | Sell |
40,700
-3,700
| -8% | -$70.1K | 0.01% | 577 |
|
|
2014
Q3 | $696K | Buy |
44,400
+900
| +2% | +$13.5K | 0.01% | 581 |
|
|
2014
Q2 | $646K | Buy |
43,500
+2,100
| +5% | +$29.6K | 0.01% | 569 |
|
|
2014
Q1 | $667K | Buy |
41,400
+3,100
| +8% | +$53K | 0.01% | 534 |
|
|
2013
Q4 | $361K | Buy |
38,300
+1,000
| +3% | +$9.76K | 0.01% | 594 |
|
|
2013
Q3 | $422K | Buy |
+37,300
| New | +$513K | 0.01% | 570 |
|
Other funds holding NBIX
DekaBank Deutsche Girozentrale's NBIX Position: Q2 2026 in Review
DekaBank Deutsche Girozentrale held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 115,973 shares worth $15.2M. The position accounts for 0.03% of the portfolio, ranked #369.
DekaBank Deutsche Girozentrale first reported a position in NBIX in Q3 2013 and has held it in 52 quarters since. The position peaked at $17.7M in Q4 2025. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- DekaBank Deutsche Girozentrale held 115,973 shares of Neurocrine Biosciences worth $15.2M as of Q2 2026.
- DekaBank Deutsche Girozentrale left its Neurocrine Biosciences share count unchanged in Q2 2026.
- Neurocrine Biosciences made up 0.03% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #369 holding.
- DekaBank Deutsche Girozentrale first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 52 quarters since.
- DekaBank Deutsche Girozentrale's Neurocrine Biosciences position peaked at $17.7M in Q4 2025.
- 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.